Drug Profile
TTP 054
Alternative Names: TTP054Latest Information Update: 18 Aug 2015
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Aug 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
- 25 Jun 2013 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Type 2 diabetes mellitus released by TransTech Pharma
- 31 May 2013 TransTech Pharma completes a phase II trial in Type-2 diabetes mellitus in USA (NCT01665352)